Metabolic · FDA Approved
Pramlintide (Symlin)
FDA-approved
01 · Overview
A synthetic analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Pramlintide has three proline substitutions intended to reduce the aggregation of human amylin, although it can still form amyloid fibrils under laboratory conditions (PMID 27665170).
Like amylin, it suppresses glucagon secretion, delays gastric emptying and promotes satiety (PMID 40332747). Symlin was FDA-approved in 2005, but all Symlin products are now listed as discontinued in FDA records.
02 · Research summary & key findings
FDA-approved in 2005 as an adjunct to mealtime insulin in type 1 and type 2 diabetes. A systematic review of randomized trials found HbA1c reductions of about 0.2-0.4% more than placebo, with weight loss versus weight gain on placebo, but more frequent nausea and severe hypoglycemia (PMID 21060125). Reviews describe improved postprandial and overall glycemic control when added to insulin (PMID 40332747).
03 · Regulatory status
Pramlintide (Symlin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Pramlintide (Symlin) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Pramlintide (Symlin) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (before meals)
References
- [1]Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus Ann Fam Med, 2010. PMID 21060125
- [2]Amyloidogenesis of the amylin analogue pramlintide Biophys Chem, 2016. PMID 27665170
- [3]Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Diabetes Ther, 2025. PMID 40332747
Primary literature
- PubMed: "Pramlintide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Pramlintide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Pramlintide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.